New hope for transplant patients: targeted combo may replace harsh chemo
NCT ID NCT06040320
First seen Nov 01, 2025 · Last updated Jun 07, 2026 · Updated 29 times
Summary
This study tests a two-drug combination (polatuzumab vedotin plus rituximab) as a first treatment for a rare blood cancer that can occur after an organ or stem cell transplant. About 12 adults who have not had prior therapy will receive the drugs to see if the combo is safe and works better than the standard single drug. The goal is to control the cancer while avoiding the severe side effects of traditional chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.